Industry news that matters to you.  Learn more

GE, J&J Deal Pairs Two Alzheimer’s Powerhouses

GE Healthcare and Johnson & Johnson are teaming up in a research pact that pairs one of the most advanced imaging agents for Alzheimer’s disease with one of the most advanced drugs being tested to fight it.

The companies said on Wednesday the deal is meant to advance efforts to find biological signals to detect Alzheimer’s disease at an earlier stage, when experts think drugs will have the best chance of making a difference.

Name You Need To Know in 2011: The S100B Blood Test

It has been coined the signature wound of the Iraq war. Traumatic brain injury has been on the rise as improvised explosive devices in Iraq and Afghanistan expose troops to more blasts and resultant head wounds than ever before.

NIH to Fund Research on Addiction-related Biomarkers

The National Institute on Drug Abuse will fund research projects that aim to identify and validate genetic variations and loci on chromosomes that are involved in drug addiction and could be used to predict the likelihood of patient response to treatments.

ExonHit Presents Promising Data on Genomic Biomarkers in Alzheimer’s Disease Clinical Trials

ExonHit Therapeutics announced today that promising data regarding the use of blood-based genomic biomarkers in Alzheimer’s disease (AD) clinical trials were disclosed in two distinct oral presentations at the Third Conference of Clinical Trials on Alzheimer’s Disease (CTAD) from November 3rd to November 5th in Toulouse, France.

Sophic to Use $750K NCI Grant to Complete Cancer Biomarker Knowledgebase

Sophic Systems Alliance has snagged a two-year, Phase II $750,000 Small Business Innovation Research Grant from the National Cancer Institute that will fund the continued development of SCan-MarK — a knowledgebase that the company is intending as a one-stop shop for cancer biomarker information for oncologists, drug developers, and cancer researchers.